Phase 3 trials suggest ways to improve current hematologic cancer therapies.

摘要

Therapeutic advances in recent years have beaten back and even defeated hematologic cancers in many patients, yet oncologists note that poor prognoses and cancer death rates remain significant. At the 49th Annual Meeting of the American Society of He-matology, held here in December, researchers discussed some of the latest efforts to advance the treatment of hematologic cancers, including Hodg-kin and non-Hodgkin lymphomas, leukemia, and multiple myeloma.